Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
110. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman<br />
DR, Henderson IC, Barcos M, Hayes D, Norton L 2000 H<strong>ER</strong>-2/neu and p53<br />
expression versus tamoxifen resistance in estrogen receptor-positive, node-<br />
positive breast cancer. J Clin Oncol 18:3471-9<br />
111. Dowsett M, Houghton J, Baum M, Salter J, A'Hern R, Iden C, Farndon J,<br />
Party obotCBBW 1999 <strong>ER</strong>, PgR, c-<strong>ER</strong>B2 and EGFR in patients randomized to<br />
adjuvant tamoxifen: combinations of biomarkers as discriminants of treatment<br />
benefit. Breast Cancer Research and Treatment 57<br />
112. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM 2005 Can<br />
molecular markers predict when to implement treatment with aromatase inhibitors<br />
in invasive breast cancer? Clin Cancer Res 11:4835-42<br />
113. Giltnane JM, Ryden L, Cregger M, Bendahl PO, Jirstrom K, Rimm DL 2007<br />
Quantitative measurement of epidermal growth factor receptor is a negative<br />
predictive factor for tamoxifen response in hormone receptor positive<br />
premenopausal breast cancer. J Clin Oncol 25:3007-14<br />
114. Viale G, Regan M, Dell'Orto P, Del Curto B, Braye S, Orosz Z, Brown R,<br />
Olszewski WP, Knox F, Oehlschlegel C, Thürlimann B Central review of <strong>ER</strong>,<br />
PgR and H<strong>ER</strong>-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant<br />
therapy for postmenopausal women with receptor positive breast cancer. 28th<br />
San Antonio Breast Cancer Symposium (abstract 44). Breast Cancer Res and<br />
Treat 2005; 94 Suppl 1, San Antonio, Texas, 2005<br />
115. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thurlimann<br />
B, Paridaens R, Monnier A, Lang I, Wardley A, Nogaret JM, Gelber RD,<br />
57
Change language